Compare Byrna Technologies Inc (BYRN) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Byrna Technologies Inc vs Revvity Inc — how do they compare? Byrna Technologies Inc trades at $3.62 (market cap $80.33M), while Revvity Inc trades at $111.3 (market cap $12.41B). The key difference: Revvity Inc is far larger — about 154.5× Byrna Technologies Inc's market cap, and Revvity Inc pays a 0.25% dividend while Byrna Technologies Inc pays none. Which is the better fit depends on your goals.
| BYRN | RVTY | |
|---|---|---|
Market Cap | $80.33M | $12.41B |
Sector | Technology | Technology |
52-Week High | $27.63 | $117.75 |
52-Week Low | $3.54 | $82.26 |
Enterprise Value | $71.94M | $14.90B |
Dividend Yield | — | 0.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BYRN trades at $3.82, down 1.16% today, with a bearish technical signal from moving averages. Recent Q2 2026 results showed a significant miss with a $0.44 EPS loss versus -$0.10 expected, amid a 42.5% revenue decline. The company is undergoing a marketing reset and acquired HERO Defense Systems to expand its product portfolio. Net income margin turned negative at -3.39% for 2026, though gross margin remains strong at 52.51%.
Outlook is cautious due to execution risks in sales turnaround efforts. Analyst consensus is bullish with 71% buy ratings, but near-term challenges in e-commerce traffic and conversion pose headwinds. The stock's valuation appears reasonable with P/S of 0.76, but profitability concerns and ongoing legal investigations present substantial risks for investors.
RVTY trades at $111.11, down 1.05% today, with a bullish technical signal from moving averages. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $1.06 exceeding expectations. Recent developments include AI integration with Anthropic's Claude and FDA clearance for a testosterone assay, signaling innovation in diagnostics and life sciences.
The outlook remains positive with strong analyst support (51.72% buy ratings) and a consensus price target of $111.43. Key risks include margin pressure from China divestment plans and weak academic demand. Revenue stability around $2.9B supports valuation, though high P/E of 53.47 requires sustained growth to justify.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Byrna Technologies Inc
Byrna Technologies specializes in less-lethal personal security devices. It develops and manufactures innovative handheld launchers and projectiles designed for self-defense, law enforcement, and private security use.
Read more on BYRN →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
